Part of our Psychedelics 2021: A Year in Review Series See the full series If public company valuations are anything to go by, it’s been a difficult year for the psychedelics sector. Many companies in the space have seen their share prices slashed, with ETFs like PSYK down over 50% since inception. But, a focus on public companies (of which there are now around fifty) and their share prices alone…
